Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 434

Results For "UP"

8388 News Found

Sigachi Industries unveils new products PureCoat and UltraMod
News | August 21, 2024

Sigachi Industries unveils new products PureCoat and UltraMod

Sigachi's entry into the coatings market is strategically timed to capitalize on the industry's growth potential


Antara AGEasy celebrates one year of advancing senior health solutions
Healthcare | August 21, 2024

Antara AGEasy celebrates one year of advancing senior health solutions

AGEasy has made significant strides in addressing the pressing health concerns of seniors in India


Procter & Gamble Health reports Q4 sales at Rs. 277 Cr
News | August 21, 2024

Procter & Gamble Health reports Q4 sales at Rs. 277 Cr

The company recorded sales of Rs. 1,129 crore for the fiscal year ended June 30, 2024,


Granules India receives ANDA approval for Glycopyrrolate Oral Solution
Drug Approval | August 20, 2024

Granules India receives ANDA approval for Glycopyrrolate Oral Solution

Glycopyrrolate Oral Solution is an anticholinergic medication indicated for pediatric patients


Health Minister Nadda reviews Monkeypox situation and preparedness
Policy | August 19, 2024

Health Minister Nadda reviews Monkeypox situation and preparedness

Monkeypox infections are usually self-limiting lasting between 2-4 weeks and patients generally recover with supportive management


CIDSCON 2024 discusses actionable efforts to tackle antimicrobial resistance
News | August 19, 2024

CIDSCON 2024 discusses actionable efforts to tackle antimicrobial resistance

The emergence of new infections in India is a growing concern


Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP
News | August 19, 2024

Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP

This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers


EMA validates Bristol Myers Squibb’s application for CAR T cell therapy Breyanzi for relapsed or refractory follicular lymphoma
News | August 19, 2024

EMA validates Bristol Myers Squibb’s application for CAR T cell therapy Breyanzi for relapsed or refractory follicular lymphoma

Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile